1. Home
  2. PRLD vs NRT Comparison

PRLD vs NRT Comparison

Compare PRLD & NRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRLD
  • NRT
  • Stock Information
  • Founded
  • PRLD 2016
  • NRT 1975
  • Country
  • PRLD United States
  • NRT United States
  • Employees
  • PRLD N/A
  • NRT N/A
  • Industry
  • PRLD Medicinal Chemicals and Botanical Products
  • NRT Oil & Gas Production
  • Sector
  • PRLD Health Care
  • NRT Energy
  • Exchange
  • PRLD Nasdaq
  • NRT Nasdaq
  • Market Cap
  • PRLD 44.0M
  • NRT 46.4M
  • IPO Year
  • PRLD 2020
  • NRT N/A
  • Fundamental
  • Price
  • PRLD $1.19
  • NRT $5.18
  • Analyst Decision
  • PRLD Strong Buy
  • NRT
  • Analyst Count
  • PRLD 3
  • NRT 0
  • Target Price
  • PRLD $4.00
  • NRT N/A
  • AVG Volume (30 Days)
  • PRLD 223.1K
  • NRT 49.1K
  • Earning Date
  • PRLD 11-05-2025
  • NRT 08-29-2025
  • Dividend Yield
  • PRLD N/A
  • NRT 9.12%
  • EPS Growth
  • PRLD N/A
  • NRT 24.05
  • EPS
  • PRLD N/A
  • NRT 0.59
  • Revenue
  • PRLD $7,000,000.00
  • NRT $6,184,173.00
  • Revenue This Year
  • PRLD N/A
  • NRT N/A
  • Revenue Next Year
  • PRLD N/A
  • NRT N/A
  • P/E Ratio
  • PRLD N/A
  • NRT $8.86
  • Revenue Growth
  • PRLD N/A
  • NRT 18.55
  • 52 Week Low
  • PRLD $0.61
  • NRT $3.88
  • 52 Week High
  • PRLD $5.53
  • NRT $5.75
  • Technical
  • Relative Strength Index (RSI)
  • PRLD 56.86
  • NRT 49.93
  • Support Level
  • PRLD $1.10
  • NRT $4.90
  • Resistance Level
  • PRLD $1.26
  • NRT $5.38
  • Average True Range (ATR)
  • PRLD 0.15
  • NRT 0.14
  • MACD
  • PRLD -0.00
  • NRT -0.01
  • Stochastic Oscillator
  • PRLD 70.65
  • NRT 58.33

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

About NRT North European Oil Royality Trust

North European Oil Royalty Trust holds overriding royalty rights covering gas and oil production in certain concessions or leases in the Federal Republic of Germany. The properties of the trust are overriding royalty rights on sales of gas, sulfur, and oil under certain concessions or leases in the Federal Republic of Germany. The trust also holds other royalty rights, which are based on leases. It receives various percentages of royalties on the proceeds of the sales of certain products from the areas involved.

Share on Social Networks: